What is the potential drug interaction between VELASOF (Sofosbuvir) / SOVIHEP (Sofosbuvir) and Metoclopramide?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

VELASOF/SOVIHEP V (sofosbuvir/velpatasvir) and metoclopramide can be safely taken together without dose adjustments, as there is no significant drug interaction between them. VELASOF/SOVIHEP V is a direct-acting antiviral combination used to treat hepatitis C, while metoclopramide is a prokinetic agent used for gastrointestinal disorders. The medications work through different mechanisms and are metabolized via different pathways. Sofosbuvir is primarily metabolized through the liver but not through the CYP450 system that commonly causes drug interactions, while velpatasvir is metabolized by CYP2B6, CYP2C8, and CYP3A4. Metoclopramide is primarily excreted by the kidneys and has minimal liver metabolism.

According to a study published in 2021 1, drug-drug interactions occur when one drug adds to or diminishes the effect of another drug, and such interactions cause 26% of all adverse drug events. However, in the case of VELASOF/SOVIHEP V and metoclopramide, their different mechanisms and metabolism pathways suggest a low risk of significant interaction.

It's essential to note that, as with any medication combination, it's advisable to monitor for any unusual side effects when starting these medications together. If you experience any concerning symptoms, contact your healthcare provider promptly. A study published in 2022 2 emphasizes the importance of understanding and managing common drug interactions to avoid adverse events and optimize patients' medicines use.

In the context of hepatitis C treatment, a study published in 2015 3 highlights the efficacy and safety of sofosbuvir-containing regimens, including VELASOF/SOVIHEP V. Another study published in 2014 4 summarizes the current clinical experience with sofosbuvir, showing that it is safe, efficacious, and well-tolerated in all genotypes.

While a study published in 2017 5 discusses the importance of focusing on clinically relevant drug-drug interactions, it does not specifically address the interaction between VELASOF/SOVIHEP V and metoclopramide. However, based on the available evidence, it is recommended to monitor patients for any unusual side effects when taking these medications together, but no dose adjustments are necessary.

References

Research

Understanding and managing common drug interactions.

Nursing standard (Royal College of Nursing (Great Britain) : 1987), 2022

Research

Sofosbuvir (Sovaldi) for the treatment of hepatitis C.

Expert review of clinical pharmacology, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.